AGC Biologics A/S: Financial statements 2022
CVR: 25950941
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
AGC Biologics A/S (CVR 25950941) has filed annual accounts for 2022. In 2022, the company reported revenue of DKK 2,517,996,000 and a net result of DKK 598,949,000 compared with DKK 571,735,000 the year before. That is an increase of 15.2% compared with the year before. The profit margin was 23.8%. Equity in the 2022 report amounted to DKK 661,277,000. The solvency ratio was 19.2%. The company had 894 employees in the financial year.
- Revenue
- DKK 2,517,996,000
- Gross Profit
- DKK 936,958,000
- Profit/Loss
- DKK 598,949,000
- Equity
- DKK 661,277,000
- Total Assets
- DKK 3,439,426,000
- Employees
- 894
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | 2.5B | 937M | 598.9M | 661.3M | 894 |
| 2021 | 2.2B | 831.9M | 571.7M | 633.6M | 730 |
| 2020 | 1.5B | 452M | 278.5M | 339.7M | 441 |
| 2019 | 996.1M | 257.1M | 154.3M | 215.1M | 377 |
| 2018 | 692.6M | 162.3M | 96.2M | 316.8M | 312 |
Official annual report
Keep an eye on AGC Biologics A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of September 1, 2022, Akira Nakamura has joined the board of directors of AGC Biologics A/S.
As of September 1, 2022, Hiroshi Nishimura has left the board of directors of AGC Biologics A/S.
AGC Biologics A/S has published its annual report for 2021. Revenue came to DKK 2,185,033,000, and the net result was DKK 571,735,000.
As of March 4, 2022, Andrea Celia Porchia is registered as adm. dir. of AGC Biologics A/S.
As of March 4, 2022, Kasper Møller has stepped down as director of AGC Biologics A/S.
About AGC Biologics A/S
AGC Biologics A/S is a Danish company of the type Aktieselskab based in Søborg, founded in 2001. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named CMC BIOLOGICS A/S and CMC BIOPHARMACEUTICALS A/S. The management consists of Kasper Møller. The board consists of Tadashi Murano (chair), Alberto Santagostino, Kasper Møller and Mai Iwaya. The company is owned by Asahi Glass Co., Ltd.. The company has 1,503 employees (2026). In 2025, the company reported revenue of DKK 1,959,639,000 and a net result of DKK -328,010,000 compared with DKK -115,005,000 the year before. Equity in the 2025 report amounted to DKK 312,021,000.
